Our experimental finding that HAT inhibition ameliorates this phenomenon adds to the existing evidence that aberrant histone modifications are responsible for atypical and deleterious gene expression in CTCL. The gene discussed is TMPRSS11D; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.